TC Biopharm (Holdings) Stock Forecast

TCBP's stock price has decreased by -95.18% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 1 analyst with a 12-month price forecast for TCBP stock has a target of 1,400, which predicts an increase of 94,815.25% from the current stock price of 1.48.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$1,400	$1,400	$1,400	$1,400
Change	+94815.3%	+94815.3%	+94815.3%	+94815.3%

* Price targets were last updated on Apr 27, 2023.

Analyst Ratings

According to 1 stock analyst, the rating for TCBP is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '23	Feb '23	Mar '23	Apr '23
Strong Buy	2	2	2	1
Buy	0	0	0	0
Hold	0	0	0	0
Sell	0	0	0	0
Strong Sell	0	0	0	0
Total	2	2	2	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mitchell Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $1,800 → $1,400	Strong Buy	Maintains	$1,800 → $1,400	+94,815.25%	Apr 27, 2023
Mitchell Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $1,800	Strong Buy	Initiates	$1,800	+121,933.90%	Jan 26, 2023
Constantine Davides EF Hutton	EF Hutton	Strong Buy Initiates $50,000	Strong Buy	Initiates	$50,000	+3,389,730.51%	Mar 28, 2022

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

n/a

from -19.20

EPS Next Year

n/a

Year	2019	2020	2021	2022	2023
Revenue	3.43M	1.98M	1.98M	3.84M	-
Revenue Growth	-	-42.26%	-	94.30%	-
EPS	-340.00	-288.40	-695.20	-38.20	-19.20
EPS Growth	-	-	-	-	-
No. Analysts	-	-	-	-	-

Financial currency is GBP. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue
High
Avg
Low

Revenue Growth

Revenue Growth
High
Avg
Low

EPS Forecast

EPS
High
Avg
Low

EPS Growth

EPS Growth
High
Avg
Low

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.